由于全球的拖延和监管问题,Piramal Pharma的26财政年度收入减少,但成本控制和战略行动支持了复苏和增长。 Piramal Pharma saw lower FY26 revenues due to global delays and regulatory issues, but cost controls and strategic moves supported recovery and growth.

Piramal Pharma报告说,由于库存调整、延迟订单以及美国境外吸入麻醉药物的监管倒退,26财政年度的收入较低,但欧洲专利开发协会得到了成本控制的支持。 Piramal Pharma reported lower revenues in FY26 due to inventory adjustments, delayed orders, and regulatory setbacks for inhalation anesthesia outside the U.S., but EBITDA was supported by cost controls. 2025年10月开始复苏,其驱动因素是生物药品资金的改善和并购活动的增加。 A recovery began in October 2025, driven by improved biopharma funding and increased M&A activity. 该公司正在扩大Lexington和Riverview设施,投资9 000万美元,吸引了强烈的海外兴趣。 The company is expanding its Lexington and Riverview facilities with a $90 million investment, attracting strong onshoring interest. 它从Bristol-Myers Squibb获得Kenalogá,预付3 500万美元,并支付多达6 500万美元的应急付款。 It acquired Kenalog® from Bristol-Myers Squibb for $35 million upfront and up to $65 million in contingent payments. Piramal在30次检查中保持了“零审调处”的合规记录,包括美国食品和食品管理局的两次审计,并仍然对长期增长有信心,以历史上强劲的Q4表现为例。 Piramal maintained a 'Zero OAI' compliance record across 30 inspections, including two USFDA audits, and remains confident in long-term growth, citing historically strong Q4 performance.